Literature DB >> 9110111

Clinical efficacy of propantheline bromide in neurocardiogenic syncope: pharmacodynamic implications.

J C Yu1, R J Sung.   

Abstract

The pharmacological response with tilt-table testing predicts long-term efficacy in neurocardiogenic syncope. However, beta-blockers for neurocardiogenic syncope are often not tolerated or are ineffective. Since cholinergic tone is important in the efferent part of the neurocardiogenic reflex, we investigated the pharmacodynamics and efficacy of propantheline bromide in preventing neurocardiogenic syncope. We studied 16 patients (11 males) with a mean age of 48.8 (+/- 15.1) years with presyncope or syncope and who had positive baseline tilt-table studies at a mean of 15.8 (+/- 10.3) minutes into the upright 60 degrees tilt. They were given propantheline bromide orally, an anticholinergic agent, at a dose of 64.3 (+/- 21.8) mg/day for 7 days, and tilt-table testing was repeated 1 hour after readministration of propantheline bromide, 30 mg orally. After propantheline bromide treatment, 13 of 16 patients (81%) had no inducible presyncope or syncope on repeat tilt-table testing. In this group of responders, the mean minimum heart rate during upright tilt-table testing increased from 43.2 (+/- 77.3) beats/min to 77.3 (+/- 17.2) beats/min after propantheline bromide (p < 0.005). More significantly, the minimum mean arterial blood pressure increased from 42.2 (+/- 25) mmHg to 81.3 (+/- 16.7) mmHg (p < 0.0005) during upright tilt. At a follow-up of 15.2 (+/- 7.4) months, in the responder group (12 patients with long-term follow-up), the average dose of propantheline bromide was 32.5 (+/- 23.8) mg/day, which was significantly reduced from the initial dose (p < 0.05). A clinical recurrence of symptoms occurred in only 4 out of 12 patients on propantheline bromide (33%), none of which were directly attributable to drug failure. It was concluded from this study that propantheline bromide is highly effective in preventing neurocardiogenic syncope. In addition, propantheline bromide's effectiveness is more than would be expected by prevention of cardioinhibition in neurocardiogenic syncope and would support a role for direct cholinergic control of vascular tone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9110111     DOI: 10.1007/bf00053025

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  6 in total

Review 1.  Neurally mediated syncope.

Authors:  M Zaqqa; A Massumi
Journal:  Tex Heart Inst J       Date:  2000

2.  An old drug for use in the prevention of sudden infant unexpected death due to vagal hypertonia.

Authors:  Pier Paolo Bassareo; Valentina Bassareo; Donatella Manca; Vassilios Fanos; Giuseppe Mercuro
Journal:  Eur J Pediatr       Date:  2011-08-04       Impact factor: 3.183

Review 3.  Strategy for the management of vasovagal syncope.

Authors:  Daniel M Bloomfield
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

4.  Preliminary observations on the effect of amitriptyline treatment in preventing syncope recurrence in patients with vasovagel syncope.

Authors:  Ergün Bariş Kaya; Gülcan Abali; Kudret Aytemir; Sedat Köse; Uğur Kocabaş; Lale Tokgözoğlu; Giray Kabakçi; Basri Amasyali; Hilmi Ozkutlu; Nasih Nazli; Ali Oto
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-04       Impact factor: 1.468

5.  South Korean geriatrics on Beers Criteria medications at risk of adverse drug events.

Authors:  Grace Juyun Kim; Kye Hwa Lee; Ju Han Kim
Journal:  PLoS One       Date:  2018-03-15       Impact factor: 3.240

6.  In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope.

Authors:  Tijana Bojić; Vladimir R Perović; Sanja Glišić
Journal:  Front Neurosci       Date:  2016-01-21       Impact factor: 4.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.